Valeant Pharmaceuticals has announced the addition of G. Mason Morfit, president of ValueAct Capital, to its Board of Directors effective immediately. Morfit previously served on the Board from May 2007 to May 2014 and is a former director of CR Bard, Immucor, Advanced Medical Optics, Solexa and MSD Performance. Prior to ValueAct Capital, Morfit worked in equity research for Credit Suisse First Boston’s healthcare group covering the managed care industry. Currently, he also serves on the Microsoft Corp. Board of Directors.
“I am pleased to welcome Mason back to the Valeant Board of Directors,” said J. Michael Pearson, chairman and CEO of Valeant. “Although Mason has not officially been a part of the Valeant Board for more than a year, I have continued to value his vision and guidance, and I believe his insights will be invaluable during this time.”
